StartsideBHC • TSE
Bausch Health Companies Inc
10,77 $
29. jan., 17:40:00 GMT-5 · CAD · TSE · Ansvarsfraskrivelse
AksjeVerdipapir notert i CAMed hovedkvarter i CA
Forrige sluttkurs
10,95 $
Dagsintervall
10,74 $ - 11,11 $
Årsintervall
5,45 $ - 15,43 $
Markedsverdi
3,90 mrd. CAD
Gjennomsnittlig volum
221,36k
P/E-tall
-
Utbytte
-
CDP-klimapoengsum
D
Markedsnyheter
Økonomi
Resultatregnskap
Omsetning
Nettoomsetning
(USD)sep. 2024Endring år til år
Omsetning
2,51 mrd.12,15 %
Driftskostnader
1,27 mrd.13,29 %
Nettoomsetning
−85,00 mill.77,51 %
Netto resultatmargin
−3,3979,93 %
Fortjeneste per aksje
1,129,34 %
EBITDA
866,00 mill.8,93 %
Faktisk avgiftssats
−338,10 %
Totale aktiva
Totale passiva
(USD)sep. 2024Endring år til år
Kontant / kortsiktige inv.
719,00 mill.−5,39 %
Totale aktiva
26,54 mrd.−1,94 %
Totale passiva
26,78 mrd.−1,89 %
Total egenkapital
−242,00 mill.
Utestående aksjer
367,80 mill.
P/B-forhold
−3,43
Avkastning på aktiva
5,13 %
Avkastning på kapital
6,37 %
Netto kontantstrøm
(USD)sep. 2024Endring år til år
Nettoomsetning
−85,00 mill.77,51 %
Kontantstrøm fra drift
405,00 mill.43,62 %
Kontanter fra investering
−102,00 mill.94,60 %
Kontanter fra finansiering
−189,00 mill.−110,41 %
Netto kontantstrøm
127,00 mill.−33,85 %
Fri kontantstrøm
606,75 mill.261,43 %
Om
Bausch Health Companies Inc. is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products. Bausch Health's business model is primarily focused on acquiring small pharmaceutical companies and then sharply increasing the prices of the drugs these companies sell. Valeant was originally founded in 1959, as ICN Pharmaceuticals by Milan Panić in California. During the 2010s, Valeant adopted a strategy of buying up other pharmaceutical companies which manufactured effective medications for a variety of medical problems, and then increasing the price of those medications. As a result, the company grew rapidly and in 2015 was the most valuable company in Canada. Valeant was involved in a number of controversies surrounding drug price hikes and the use of a specialty pharmacy for the distribution of its drugs. This led to an investigation by the U.S. Wikipedia
Administrerende direktør
Grunnlagt
1959
Ansatte
20 270
Søk
Slett søket
Lukk søkefunksjonen
Google-apper
Hovedmeny